We recently published a list of 7 Best Nanotech Penny Stocks to Invest In. In this article, we are going to take a look at where NanoViricides Inc. (NYSEAMERICAN:NNVC) stands against other best nanotech penny stocks to invest in.
Nanotech involves working with tiny particles which are about the size of molecules. This field is being used to improve products in many different industries, like electronics, medicine, and energy. By manipulating matter at this tiny scale, materials and devices with special properties can be made. The global nanotech market was valued at $3.69 billion in 2022 and is projected to grow at a 33.1% CAGR from 2023 to 2030, as reported by Grand View Research. This is driven by the increased use in medical diagnostics and imaging, technological advancements, substantial R&D funding, and the creation of advanced materials for healthcare, electronics, aerospace, textiles, transportation, manufacturing, and agriculture.
In 2022, nanodevices dominated the nanotech market, accounting for over 58% of global revenue. This was due to their potential in healthcare (targeted drug delivery, imaging, diagnostics, regenerative medicine) and electronics (smaller transistors, memory devices, sensors). Nanosensors, which are crucial for nanoscale detection and measurement across many industries, are projected to grow. Healthcare and pharmaceuticals led applications in 2022, with over 26% market share. This was driven by the increased use of nanotech in areas like surgical nano-robots, nano-diagnostics, and targeted drug delivery, as well as rising chronic disease prevalence and surgical procedures. The automobile segment is also expected to grow due to nanotech’s improvements in materials, energy efficiency, safety, and functionality.
While the nanotech industry as a whole holds promise, it is still in its early innings and many companies are in the small-cap territory.
Methodology
We first sifted through ETFs, online rankings, and internet lists to compile a list of the top nanotech stocks under $5. We then selected the 7 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q3 2024. The hedge fund data was sourced from Insider Monkey’s database which tracks the moves of over 900 elite money managers.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A scientist in a laboratory holding a test tube filled with a glowing blue solution, representing the company’s nano-biopharmaceutical research and development.
NanoViricides Inc. (NYSEAMERICAN:NNVC)
Number of Hedge Fund Holders: 1
Share Price as of February 11: $1.3
NanoViricides Inc. (NYSEAMERICAN:NNVC) is a clinical-stage nanobiopharmaceutical company that develops antiviral drugs. Its Nanoviricide platform technology uses nanotech to target and treat various viral infections. These include RSV, influenza, and COVID-19, with candidates ranging from oral formulations to injectable and inhaled treatments.
The company’s broad-spectrum antiviral drug candidate, NV-387, is its major focus. This drug is designed to mimic features of host cells and target viruses in a way that makes it difficult for them to mutate and escape its effects. NV-387 has shown promising activity against a variety of viruses in preclinical studies. These include MPOX/Smallpox, RSV, Influenza, and COVID. It has demonstrated superior activity compared to existing influenza drugs in animal models.
The company has completed a Phase Ia/Ib clinical trial in healthy subjects, with no reported adverse events. It’s now preparing to initiate Phase II clinical trials, prioritizing MPOX infection in Central Africa and RSV infection in the USA. As of September 30, 2024, NanoViricides Inc. (NYSEAMERICAN:NNVC) had ~$3.87 million in cash and cash equivalents. While it raised additional funds since the reporting period, the company publicly stated that its current funding is not sufficient to complete the planned Phase II trials through November 14, 2025.
Overall, NNVC ranks 5th on our list of best nanotech penny stocks to invest in. While we acknowledge the growth potential of NNVC, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NNVC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
